AhR expression and signaling are altered in many inflammatory skin disorders such as AD and psoriasis, and clinical trials with tapinarof (first-in-class, non-steroidal, topical AhR agonist) have validated AhR as a therapeutic target capable of delivering significant efficacy [41]. Here, AHR is linked to inflammatory skin disease.